The World CNS Summit South Korea is the premier industry-focused forum dedicated to advancing targeted, mechanism-differentiated therapies for neurodegenerative, rare neurodevelopmental, and neuropsychiatric disorders. As South Korea emerges as a major center for neuroscience innovation, the summit convenes biopharma leaders, translational scientists, and drug developers to explore the next generation of CNS therapeutics and accelerate progress from discovery through early clinical development.

The agenda highlights advances in disease-modifying approaches, blood-brain barrier delivery technologies, RNA-based therapeutics, gene therapies, neuroinflammation, biomarkers, and novel targets beyond traditional amyloid and tau pathways. Attendees will gain insights from leading organizations including ABL Bio, AriBio, Johnson & Johnson, Eli Lilly, Novartis, Takeda, AbbVie, Lundbeck, Angelini Pharma and many more.

Designed to foster meaningful scientific exchange and strategic collaboration, the summit provides a valuable platform to connect with Korean biotech innovators, global pharmaceutical companies, and external innovation leaders evaluating the next wave of CNS opportunities. For decision-makers shaping neuroscience pipelines, partnerships, and licensing strategies, it offers a focused view of the technologies, modalities, and therapeutic approaches driving the future of CNS drug development.

Find out more today: https://ter.li/jrf94t4n